


## Vector Map: pENTR/D-TOPO

**NAME:** pENTR/D-TOPO  
**RESISTANT MARKER:** Kanamycin resistant; 25 µg/ml  
**SOURCE:** Invitrogen Life Technologies  
**V\_TYPE:** Gateway entry vector  
**SEQUENCING PRIMERS:** M13(-21), M13 reverse, T7

### POLYLINKER SEQUENCE:

```

TAACGCTAGCATGGATGTTTTCCAGTCACGACGTTGTAAAACGACGGCC
AGTCTTAAGCTCGGGCCCCAAATAATGATTTTATTTTGACTGATAGTGAC
CTGTTTCGTTGCAACAAATTGATGAGCAATGCTTTTTTATAATGCCAACTT
TGTACAAAAAAGCAGGCTCCGCGGCCGCCCTTCACC-ORF-AAGGGTG
GGCGCGCCGACCCAGCTTTCTTGTACAAAGTTGGCATTATAAGAAAGCAT
TGCTTATCAATTTGTTGCAACGAACAGGTCAGTATCAGTCAAAATAAAAT
CATTATTTGCCATCCAGCTGATATCCCTATAGTGAGTCGTATTACATGG
TCATAGCTGTTTCCTGGCAGCTCTG
    
```



## Sequence:

```
1      CTTTCCTGCG TTATCCCCTG ATTCTGTGGA TAACCGTATT ACCGCCTTTG AGTGAGCTGA 60
61     TACCGTCTCG CGCAGCCGAA CGACCGAGCG CAGCGAGTCA GTGAGCGAGG AAGCGGAAGA 120
121    GCGCCCAATA CGCAAACCGC CTCTCCCCGC GCGTTGGCCG ATTCATTAAT GCAGCTGGCA 180
181    CGACAGGTTT CCCGACTGGA AAGCGGGCAG TGAGCGCAAC GCAATTAATA CGCGTACCGC 240
241    TAGCCAGGAA GAGTTTGTAG AAACGCAAAA AGGCCATCCG TCAGGATGGC CTTCTGCTTA 300
301    GTTTGATGCC TGGCAGTTTA TGGCGGGCGT CCTGCCCGCC ACCCTCCGGG CCGTTGCTTC 360
361    ACAACGTTCA AATCCGCTCC CGGCGGATTT GTCCTACTCA GGAGAGCGTT CACCGACAAA 420
421    CAACAGATAA AACGAAAGGC CCAGTCTTCC GACTGAGCCT TTCGTTTTAT TTGATGCCTG 480
481    GCAGTTCCCT ACTCTCGCGT TAACGCTAGC ATGGATGTTT TCCCAGTCAC GACGTTGTAA 540
541    AACGACGGCC AGTCTTAAGC TCGGGCCCCA AATAATGATT TTATTTTGAC TGATAGTGAC 600
601    CTGTTTCGTT CAACAAATTG ATGAGCAATG CTTTTTTATA ATGCCAACTT TGTACAAAAA 660
661    ACGTAGCCTT GCGGCGCCCG CCTTCACCAA GGTGGGGCGC GCCGACCCAG CTTTCTTGTA 720
721    CAAAGTTGGC ATTATAAGAA AGCATTGCTT ATCAATTTGT TGCAACGAAC AGGTCACTAT 780
781    CAGTCAAAAT AAAATCATTA TTTGCCATCC AGCTGATATC CCTATAGTGT AGTCGTATTA 840
841    CATGGTCATA GCTGTTTCCT GGCAGCTCTG GCCCGTGTCT CAAAATCTCT GATGTTACAT 900
901    TGCAAGAATA AAAAAATATAT CATCATGAAC AATAAACTG TCTGCTTACA TAAACGTAA 960
961    TACAAGGGGT GTTATGAGCC ATATTCAACG GGAACGTCG AGGCCGCGAT TAAATTCCAA 1020
1021   CATGGATGCT GATTTATATG GGTATAAATG GGCTCGCGAT AATGTCGGGC AATCAGGTGC 1080
1081   GACAATCTAT CGCTTGATATG GGAAGCCCGA TGCGCCAGAG TTGTTTCTGA AACATGGCAA 1140
1141   AGGTAGCCTT GCCAATGATG TTACAGATGA GATGGTCAGA CTAAACTGCG TGACGGAATT 1200
1201   TATGCCTCTT CCGACCATCA AGCATTTTAT CCGTACTCCT GATGATGCAT GGTTACTCAC 1260
1261   CACTGCGATC CCCGAAAAAA CAGCATTTCA GGTATTAGAA GAATATCCTG ATTCAGGTGA 1320
1321   AAATATTGTT GATGCGCTGG CAGTGTTCCT GCGCCGGTTG CATTCGATTC CTGTTTGTA 1380
1381   TTGTCCTTTT AACAGCGATC CGGTATTTCC TCTCGCTCAG GCGCAATCAC GAATGAATA 1440
1441   CGGTTTGCTT GATGCGAGTG ATTTTGATGA CGAGCGTAAT GGCTGGCCTG TTGAACAAGT 1500
1501   CTGGAAAGAA ATGCATAAAC TTTTGCCATT CTCACCGGAT TCAGTCGTCA CTCATGGTGA 1560
1561   TTTCTCACTT GATAACCTTA TTTTGGACGA GGGGAAATTA ATAGGTTGTA TTGATGTTGG 1620
1621   ACGAGTCGGA ATCGCAGACC GATACCAGGA TCTTGCCATC CTATGGAACT GCCTCGGTGA 1680
1681   GTTTTCTCCT TCATTACAGA AACGGCTTTT TCAAAAATAT GGTATTGATA ATCCTGATAT 1740
1741   GAATAAATTG CAGTTTCATT TGATGCTCGA TGAGTTTTTC TAATCAGAAAT TGGTTAATTG 1800
1801   GTTGTAACAC TGGCAGAGCA TTACGCTGAC TTGACGGGAC GGCAGCAAGCT CATGACCAAA 1860
1861   ATCCCTTAAC GTGAGTTACG CGTCGTTCCA CTGAGCGTCA GACCCCGTAG AAAAGATCAA 1920
1921   AGGATCTTCT TGAGATCCTT TTTTCTGCG CGTAATCTGC TGCTTGCAAA CAAAAAAACC 1980
1981   ACCGCTACCA GCGGTGGTTT GTTTGCCGGA TCAAGAGCTA CCAACTCTTT TTCCGAAGGT 2040
2041   AACTGGCTTC AGCAGAGCGC AGATAACAAA TACTGTCCTT CTAGTGTAGC CGTAGTTAGG 2100
2101   CCACCACTTC AAGAACTCTG TAGCACCGCC TACATACCTC GCTCTGCTAA TCCTGTTACC 2160
2161   AGTGGCTGCT GCCAGTGGCG ATAAGTCGTG TCTTACCGGG TTGGACTCAA GACGATAGTT 2220
2221   ACCGGATAAG GCGCAGCGGT CGGGCTGAAC GGGGGGTTTC TGACACAGC CCAGCTTGGA 2280
2281   TCGAACGACC TACACCGAAC TGAGATACCT ACAGCGTGAG CATTGAGAAA GCGCCACGCT 2340
2341   TCCCGAAGGG AGAAAGCGCG ACAGGTATCC GGTAAGCGGC AGGTCGGA CAGGAGAGCG 2400
2401   CACGAGGGAG CTTCCAGGGG GAAACGCCTG GTATCTTTAT AGTCCTGTCG GGTTTCGCCA 2460
2461   CCTCTGACTT GAGCGTCGAT TTTTGTGATG CTCGTCAGGG GGGCGGAGCC TATGGAAAAA 2520
2521   CGCCAGCAAC GCGGCCTTTT TACGGTTTCT GGCCTTTTGC TGGCCTTTTG CTCACATGTT 2580
```

All ORF clones are provided in Entry Vectors for the Invitrogen Gateway® cloning system. Invitrogen offers a whole range of Destination Vectors for a wide range of applications. Refer to the homepage of Invitrogen for further information on the Gateway® cloning system and related Invitrogen products at:

<http://www.invitrogen.com/content.cfm?pageid=4072>

For further information on the ORFeome Collaboration, visit their homepage at <http://www.orfeomecollaboration.org/html/index.shtml>.

For further technical information visit our homepage at: <http://www.dnaform.jp> or contact us under: ORF@dnaform.jp.